Daré Bioscience (DARE 0.32%), a women’s health-focused biopharmaceutical company developing new therapies and devices, announced its second quarter 2025 results on August 14, 2025. The headline news was a negative GAAP revenue figure of $21,172, falling far short of the $280,000 consensus estimate for GAAP revenue. On earnings per share (EPS), the company posted a GAAP loss of $0.45, which was a narrower loss than the expected $0.58 (GAAP). The company demonstrated lower operating expenses compared to Q2 2024, but continued to post steep losses and reported a significant working capital deficit. Overall, the quarter showed important clinical and strategic progress but underscored critical financial risks, with near-term revenue still heavily dependent on upcoming product launches.
| Metric | Q2 2025 | Q2 2025 Estimate | Q2 2024 | Y/Y Change |
|---|---|---|---|---|
| EPS | $(0.45) | $(0.58) | $1.52 | $(1.97) |
| Revenue | $(21,172) | $282,750 | $22,438 | -194.4% |
| General and Administrative Expenses | $2,377,866 | $2,448,130 | (2.9%) | |
| Research and Development Expenses | $1,428,762 | $4,933,774 | (71.0%) | |
| Working Capital (Deficit) (period end) | $(12,618,726) | N/A |
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Business Overview and Strategic Focus
The company has built its business around developing therapies and medical devices specifically addressing women’s health needs such as contraception, sexual health, and menopause symptom management. Its pipeline includes products like Sildenafil Cream for female sexual arousal disorder and Ovaprene, a hormone-free monthly contraceptive device.
Recently, it has shifted toward a dual path to commercialization. This involves launching products via the Section 503B drug compounding pathway while simultaneously seeking full approval from the U.S. Food and Drug Administration (FDA). This approach aims to bring therapies to the market sooner while continuing the lengthy approval process for wider distribution. Key success factors remain regulatory milestones, market acceptance of first-in-category products, and continued access to non-dilutive (grant) funding.
Quarter in Review: Performance, Pipeline, and Partnerships
The company reported negative GAAP revenue of -$21.172 million. This missed the small positive GAAP revenue estimate and stood in stark contrast to the prior year’s revenue, which reflected a non-recurring royalty sale. General and administrative expenses fell to $2.4 million, while research and development spending dropped sharply to $1.4 million, reflecting the benefit of grants for pipeline programs.
Pipeline progress remained central. DARE to PLAY™ Sildenafil Cream, a topical medicine for female sexual dysfunction, was on track for commercial launch through the Section 503B compounding path in late 2025. The company invested resources in market preparation, including a collaboration for direct-to-patient awareness with Rosy Wellness. The Ovaprene Phase 3 trial, investigating a hormone-free vaginal contraceptive ring, received a positive safety review from the Data Safety Monitoring Board, with no new issues detected. That study continued enrollment and confirmed pregnancy rates were as expected. Other programs advanced as well, including DARE-HPV for human papillomavirus infection (supported by federal agency grants) DARE-LARC1, a long-acting contraceptive, is in preclinical development and is expected to be fully funded by a foundation grant, with a $6 million grant installment received in July 2025.
Strategic partnerships again played a crucial role in the business model. Ongoing collaborations with Organon & Co. enabled the continued commercialization of XACIATO, and Bayer retained U.S. rights to Ovaprene. Importantly, the company intensified efforts to build additional distribution through telehealth and online channels, broadening access to planned new products. Management stressed that upcoming launches would be supported by multiple partnerships to maximize product availability, rather than relying on any single route or partner.
Revenue in the prior year (Q2 2024) was boosted by a one-time $20.4 million GAAP royalty sale, leading to an apparent profit (GAAP). In the background, liquidity continued to tighten as cash and working capital both fell, but recent new funding and grant inflows after the quarter have helped stabilize operations in the short term.
Product Families and Launch Plans
The pipeline combines prescription pharmaceuticals, such as the Sildenafil Cream formulation, with consumer health products like branded vaginal probiotics. Sildenafil Cream is being developed for topical, on-demand use in women with sexual arousal disorder and is expected to generate its first revenue in Q4 2025. Ovaprene, the investigational contraceptive ring, is still under clinical development but represents a first-in-category, hormone-free solution. The DARE-HRT1 product is a hormone therapy delivered through a monthly vaginal ring, targeting the compounded hormone therapy market. Planned for late 2026, this product expands the addressable women’s health market into menopause symptom relief. Two non-prescription probiotics are also slated for launch in the near term, intended to restore a healthy vaginal microbiome, a function supported by grant-funded research and clinical data.
Management’s dual-path strategy is to accelerate commercialization by leveraging compounding pharmacy regulations (Section 503B) which allow certain drugs to be produced and dispensed by specialist facilities, while full regulatory approval continues in parallel. This technique aims to increase patient access and improve early revenue. Supporting this, the company is developing multiple marketing and distribution partnerships, targeting telehealth, online retailers, and consumer-facing channels.
Looking Ahead: Guidance and Risks
Management reiterated goals for revenue to begin in the fourth quarter of 2025 with the launch of DARE to PLAY™ Sildenafil Cream, followed by other proprietary and consumer products. The capital position was significantly improved after Q2 2025 by a $17.6 million sale of new shares and a $6.0 million grant payment, but future operating results depend on the rapid acceptance of new products and ongoing grant support for research and development. Investors are watching for initial sales data from the new product launches and for progress in ongoing regulatory discussions, especially around the Sildenafil Cream pivotal trial and continued Ovaprene development.
Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted.
